Back to search
FDAFDA · Food and drugs·Recall number D-0877-2018

Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01

Published June 20, 2018 · Recall initiated: June 7, 2018

Summary

FDA records drug Class III recall D-0877-2018, published June 20, 2018 and initiated June 7, 2018. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 1,620 bottles; Lot: Lot #: 3087136, Exp 5/20. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Product was distributed throughout the United States
Lot
Lot #: 3087136, Exp 5/20
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01 recalled?

Yes. FDA published recall D-0877-2018 on June 20, 2018. Reported hazard: Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.

What should I do if I have this product?

Voluntary: Firm initiated · Letter